183 related articles for article (PubMed ID: 31154006)
1. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
Yao X; Wu Y; Jiang J; Hu P; Liu D; Chen X
Clin Drug Investig; 2019 Jul; 39(7):643-651. PubMed ID: 31016613
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
4. Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population.
Shin Y; Chae D; Park K
Eur J Pharm Sci; 2023 May; 184():106402. PubMed ID: 36754259
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
6. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
7. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
Yao X; Liu Y; Song L; Jiang J; Xiao F; Liu D; Hu P
Biomed Chromatogr; 2019 Mar; 33(3):e4420. PubMed ID: 30362147
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng B; Yu XQ; Greth W; Robbie GJ
Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
Rule GS; Rockwood AL; Johnson-Davis KL
Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for the treatment of multiple sclerosis.
Warnke C; Stüve O; Kieseier BC
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
14. Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Foster D; Upton RN
CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):362-71. PubMed ID: 26225264
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Bergner R; Peters L; Schmitt V; Löffler C
Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Fajardo-Robledo NS; Jacobo-Cuevas H; Perez-Guerrero EE; Corona-Sanchez EG; Saldaña-Cruz AM; Romero-Tejeda EM; Rodriguez-Jimenez NA; Totsuka-Sutto SE; Lopez-Roa RI; Ponce-Guarneros JM; Alcaraz-Lopez MF; Cerpa-Cruz S; Muñoz-Valle JF; Cardona-Muñoz EG; Gonzalez-Lopez L; Gamez-Nava JI;
Sci Rep; 2022 Feb; 12(1):1877. PubMed ID: 35115601
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
Bar-Or A
Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
